BioDuro-Sundia

The firm is privately held by Advent International and Bridgepoint, two large-cap private equity sponsors that partnered to recapitalize the business in 2019 after its separation from PPD. No founder or family ownership stake is publicly disclosed. The management team reports through a board controlled by Advent and Bridgepoint appointees.

It operates as a single-profit-center CRDMO that integrates discovery biology, chemistry, API manufacturing up to kilo scale, and oral-solid drug product under one management, whereas most large CROs run these as separate business units or partner networks. This full-stack model is marketed as 'IND enabling,' meaning a client can take a target from hit generation through an FDA-ready filing without switching providers.

Historically focused on small molecules, the firm has expanded into peptides, antibody-drug conjugates, and PROTACs via its dedicated platform groups. Large-molecule development and bioanalysis services are explicitly listed on its website, though the manufacturing scale appears concentrated in small-molecule API and oral-solid dosage forms.

Headquartered in San Diego, the firm maintains its principal laboratory and manufacturing presence in Shanghai. The October 2024 joint venture with Cenra adds API manufacturing capacity in Taiwan, supplementing the mainland China footprint.

No. It has been owned by Advent International and Bridgepoint since 2019 and files no public financial statements. Revenue and AUM figures are not publicly disclosed.

The firm's internal 'Solution Engine' and DNA-encoded library platforms target hit identification and lead optimization for preclinical biotechs, while its kilo-scale API and drug-product suites carry programs through clinical manufacturing and commercial launch readiness. This spans the continuum from discovery to post-approval supply.

BioDuro-Sundia is an operating CRDMO, not an investment vehicle. It does not maintain a corporate venture arm. Its sponsors, Advent and Bridgepoint, handle investment activity, and BioDuro forms commercial partnerships — such as the CTI Biotechnology and Cenra collaborations — rather than taking equity positions in client biotechs.